Compare Tencent Music Entertainment Group - ADR (TME) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tencent Music Entertainment Group - ADR vs State Street SPDR S&P Biotech ETF — how do they compare? Tencent Music Entertainment Group - ADR trades at $8.46 (market cap $16.09B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Tencent Music Entertainment Group - ADR pays a 2.75% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Tencent Music Entertainment Group - ADR nearer its low. Which is the better fit depends on your goals.
| TME | XBI | |
|---|---|---|
Market Cap | $16.09B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $26.36 | $164.28 |
52-Week Low | $8.16 | $86.92 |
Enterprise Value | $14.05B | — |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TME stock trades at $8.45, down 14.65% in the last session amid mixed earnings results. The company reported Q2 2026 revenue growth of 6% year-over-year but faces slowing operational growth and competitive pressures. Valuation metrics appear reasonable with a P/E of 10.29 and P/S of 2.71, while profitability remains strong with a net income margin of 26.28%. Technical indicators signal a bearish trend, with the stock near key support levels.
The outlook is cautious; while TME's fundamentals are solid with robust cash flow and profitability, near-term headwinds from competition and market sentiment pose risks. Analyst consensus is divided, with 46% buy ratings but 50% hold, reflecting uncertainty over growth sustainability. Investors should weigh the attractive valuation against execution risks in a challenging environment.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
